Search results for: Innovation Policy Prize
Filter search results
Can a continued focus on prevention, diagnosis, and treatment see the NHS to another 75 years?
27 July 2023
…J. (2012) The Many Faces of Innovation. OHE Contract Research. Available from https://www.ohe.org/publications/many-faces-innovation/ The Many Faces of Innovation – OHE Teeling Smith, G. ed. (1967) Alive to Forty-Five. OHE Monograph. Available…
Spotlight on OHE: Adaptive Pathways, Economic Evaluation, Stated Preferences and Life-cycle Price Modelling
5 November 2014
Medicines Adaptive Pathways: A Practical Strategy to Improve Patient Access to Medicines? In September 2014 the Centre for Innovation in Regulatory Science held a workshop with invited regulators, health…
A Prescription for Green Healthcare Delivery: Insights from an Expert Sustainability Webinar
19 July 2023
…refinement of products, complex supply chains, resource-intensive manufacturing and R&D, the need for constant innovation, and a lack of incentives for sustainability are barriers to achieving net-zero carbon emissions in…
Collaborating on Payment Models to Unlock the Potential of Multi-Indication Therapies.
22 June 2022, 2:00pm
Innovation in drug development is evolving at pace. Individual medicines are increasingly found to benefit patients in a range of indications within or across diseases, at different stages of disease,…
OHE in the Spotlight: Summer 2011
22 September 2011
…measures even more important. Economics of the Pharmaceutical and Life Sciences Industries Pricing pharmaceuticals in a way that both maximises patient access and encourages continued innovation remains a global challenge. …
Value Based Pricing in Sweden: Lessons for Design?
28 November 2012
…reimburse a new treatment. Sweden’s HTA system is aimed not just at controlling costs, but also at encouraging innovation by allocating funds to new and better treatments. Sweden’s willingness to…
OHE Involved in Developing New AMS Report on Stratified Medicines
15 July 2013
…to reflect this value can have significant implications for the rate of future innovation. Recognising that evidence requirements for companion diagnostics need to be flexible to limit the complexities added…
The Expanding Value Footprint of Oncology Treatments
13 May 2014
…to adequately reward important innovation and so discourage future innovation, to the detriment of society. Public policy options for addressing this challenge include, for example, pricing that varies by indication,…
Using Target Product Profiles (TPPs) to improve diagnostic testing for cancer
10 June 2024
…experts, research and innovation funders, innovators in research institutes and industry, regulators, health technology assessment expertise, policymakers and payers, and the patient voice. TPP development has two key stages: inception…